🇺🇸 FDA
Pipeline program

riliprubart placebo, solution for injection in prefilled pen (PFP), riliprubart placebo, solution for injection in vial, riliprubart, riliprubart

EFC17236

Phase 3 small_molecule active

Quick answer

riliprubart placebo, solution for injection in prefilled pen (PFP), riliprubart placebo, solution for injection in vial, riliprubart, riliprubart for Polyneuropathy, Inflammatory Demyelinating, Chronic is a Phase 3 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pharma Bristol-Myers Squibb
Indication
Polyneuropathy, Inflammatory Demyelinating, Chronic
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials